Qiagen Submits Second PMA for Therascreen KRAS Companion Dx
August 05, 2011
Qiagen Submits Second PMA for Therascreen KRAS Companion Dx
The firm completed a submission to FDA for use of the test as a companion to Erbitux, a monoclonal antibody EGFR inhibitor with sales last year of $820 million.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.